Nabriva Therapeutics AG Performance
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
The company secures a Beta (Market Risk) of -0.23, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Nabriva Therapeutics are expected to decrease at a much lower rate. During the bear market, Nabriva Therapeutics is likely to outperform the market. Nabriva Therapeutics right now secures a risk of 0.0%. Please verify Nabriva Therapeutics AG downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Nabriva Therapeutics AG will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nabriva Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Nabriva Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 47.8 M |
Nabriva |
Nabriva Therapeutics Relative Risk vs. Return Landscape
If you would invest 162.00 in Nabriva Therapeutics AG on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Nabriva Therapeutics AG or generate 0.0% return on investment over 90 days. Nabriva Therapeutics AG is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Nabriva, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nabriva Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nabriva Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nabriva Therapeutics AG, and traders can use it to determine the average amount a Nabriva Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NBRV |
Based on monthly moving average Nabriva Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nabriva Therapeutics by adding Nabriva Therapeutics to a well-diversified portfolio.
Nabriva Therapeutics Fundamentals Growth
Nabriva Stock prices reflect investors' perceptions of the future prospects and financial health of Nabriva Therapeutics, and Nabriva Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nabriva Stock performance.
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| EBITDA | (54.7 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Earnings Per Share | (19.67) X | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
About Nabriva Therapeutics Performance
Evaluating Nabriva Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nabriva Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nabriva Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Nabriva Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.Things to note about Nabriva Therapeutics performance evaluation
Checking the ongoing alerts about Nabriva Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nabriva Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nabriva Therapeutics is not yet fully synchronised with the market data | |
| Nabriva Therapeutics may become a speculative penny stock | |
| Nabriva Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M). | |
| Nabriva Therapeutics AG currently holds about 20.04 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Nabriva Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nabriva Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nabriva Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nabriva Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nabriva Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nabriva Therapeutics' stock. These opinions can provide insight into Nabriva Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |